Estimates Revisions Tempus AI, Inc. Boerse Muenchen
Stocks
F3M
US88023B1035
Biotechnology & Medical Research
|
Real-time
Boerse Muenchen
14:56:33 2026-10-08 EDT
|
5-day change | 1st Jan Change | ||
| 61.00 EUR | -3.59% |
|
-12.00% | +21.67% |
| 10-07 | Tempus Enters Multiyear Collaboration With Moderna, Merck Aimed at Commercializing Cancer Drug | DJ |
| 10-07 | Tempus Expands Moderna, Merck Collaboration for Individualized Cancer Therapy | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
Tempus AI, Inc.(TEM)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
Tempus AI, Inc.(TEM)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
Data source:
Tempus AI, Inc.(TEM)
EBIT
Dividend / Share (DPS)
Data source:
Tempus AI, Inc.(TEM)
Cash or Net Debt
- Stock Market
- Stocks
- TEM Stock
- F3M Stock
- Consensus Tempus AI, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
